Trial Profile
Efficacy of inactivated (CoronaVac and BBIBP-CorV) and adenovirus type 5 vectored (Convidecia) vaccines in China outbreak
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2022
Price :
$35
*
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; BBIBP CorV (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
- Indications COVID 2019 infections; COVID-19 pneumonia; COVID-19 respiratory infection
- Focus Therapeutic Use
- 20 Apr 2022 New trial record
- 01 Apr 2022 Results published in the Vaccine